Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Pharmigene, Inc. operates globally, specializing in the creation, production, and distribution of diagnostic testing solutions. Its offerings include molecular diagnostic tools specifically designed to detect adverse drug reactions, alongside DNA extraction products crucial for diverse applications such as gene expression analysis, clinical molecular diagnostics, human identity verification, forensic investigations, and biomedical research. The firm also provides an array of specialized services, including pharmacogenomics, drug allergy screening, and functional medicine assessments. Beyond its own products, Pharmigene distributes various genomics and genetics equipment and reagents. Complementing these, it offers a comprehensive suite of support solutions, encompassing expert consultation, training programs, analytical software, and technical assistance. Furthermore, the company extends its capabilities through Contract Development and Manufacturing Organization (CDMO) services. Pharmigene, founded in 1994, is headquartered in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.